We further tested the robustness of the TRPV2-interactome signature using another independent cohort with drug resistance (Temozolomide), progression and recurrence information, the Cancer Genome Atlas (TCGA) GBM data of 285 patients. The gene discussed is TRPV2; the disease is glioblastoma.